Two Triangle-based companies, Inspire Pharmaceuticals (Nasdaq: ISPH) and Clinipace are teaming up for Phase II clinical trials.

picked , a contract research organization, for the study of its eye treatment AzaSite. Already approved for fighting bacterial conjunctivitis, AzaSite could be used to treat an ocular disease called blepharitis.

Financial terms were not disclosed.

Clinipace will provide electronic data capture, clinical monitoring, site management, biostatistical consulting and regulatory document management. Clinipace’s web-based software, called Tempo, is designed to deliver clinical trial services at lower costs than traditional CRO solutions.

“We share a common goal with Clinipace of changing the way we approach the clinical development process – shifting away from some of the more traditional CRO processes and moving towards an integrated technology-driven model,” said Chad Ice, senior director of clinical research at Inspire. “We believe that Clinipace can help assure that communication with our clinical sites is much more seamless – one of the most vital links driving the success of our clinical trial process.”